Matinas Biopharma (NYSEAMERICAN:MTNB) Stock to Reverse Split on Monday, September 28th

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB)’s stock is set to reverse split before the market opens on Monday, September 28th. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, September 27th.

Matinas Biopharma Trading Down 1.6%

Shares of NYSEAMERICAN MTNB opened at $0.16 on Friday. The stock has a 50 day simple moving average of $0.24 and a 200-day simple moving average of $0.50. The company has a market cap of $2.36 million, a PE ratio of -0.14 and a beta of 1.70. Matinas Biopharma has a 12-month low of $0.15 and a 12-month high of $2.14.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing oral formulations of medicines that are traditionally administered by injection. The company’s technology platform, known as lipid nanocrystal (LNC) technology, is designed to encapsulate active pharmaceutical ingredients and support their delivery through the gastrointestinal tract.

Matinas’ lead investigational product is MAT2203, an oral formulation of amphotericin B, an antifungal medicine used to treat serious fungal infections.